Literature DB >> 7532860

High-dose intravenous gammaglobulin therapy for acquired von Willebrand disease.

P J Van Genderen1, D N Papatsonis, J J Michiels, J J Wielenga, J Stibbe, F J Huikeshoven.   

Abstract

Patients with acquired von Willebrand disease may present with severe bleeding, which is usually difficult to manage. Adequate haemostasis in acquired von Willebrand disease may be achieved with the infusion of factor VIII/von Willebrand factor concentrates or with the administration of desmopressin. We report a case of acquired von Willebrand disease with severe postoperative bleeding, responding poorly to classical von Willebrand factor replacement therapy but successfully treated with high-dose intravenous gammaglobulins. This new treatment mode of acquired von Willebrand disease is discussed in the light of a critical analysis of the literature.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7532860      PMCID: PMC2398043          DOI: 10.1136/pgmj.70.830.916

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  15 in total

1.  Successful treatment of an acquired von Willebrand factor antibody by extracorporeal immunoadsorption.

Authors:  J Uehlinger; E Rose; L M Aledort; R Lemer
Journal:  N Engl J Med       Date:  1989-01-26       Impact factor: 91.245

2.  The use of high-dose intravenous gamma-globulin in acquired von Willebrand syndrome.

Authors:  B G Macik; D A Gabriel; G C White; K High; H Roberts
Journal:  Arch Pathol Lab Med       Date:  1988-02       Impact factor: 5.534

3.  Acquired type II von Willebrand's disease associated with adrenal cortical carcinoma.

Authors:  T Facon; C Caron; P Courtin; A Wurtz; M Deghaye; F Bauters; C Mazurier; J Goudemand
Journal:  Br J Haematol       Date:  1992-04       Impact factor: 6.998

4.  Acquired von Willebrand disease: correction of hemostatic defect by high-dose intravenous immunoglobulins.

Authors:  A Delmer; M H Horellou; J M Bréchot; J Prudent; F Potevin; C Lecrubier; C Girard-Longhini; M Samama; R Zittoun
Journal:  Am J Hematol       Date:  1992-06       Impact factor: 10.047

5.  High-dose intravenous gammaglobulin for acquired von Willebrand's disease.

Authors:  A Delannoy; A C Saillez
Journal:  Br J Haematol       Date:  1988-11       Impact factor: 6.998

6.  The efficacy of intensive plasma exchange in acquired von Willebrand's disease.

Authors:  L E Silberstein; J Abrahm; S J Shattil
Journal:  Transfusion       Date:  1987 May-Jun       Impact factor: 3.157

7.  Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies.

Authors:  P M Mannucci; R Lombardi; R Bader; M H Horellou; G Finazzi; C Besana; J Conard; M Samama
Journal:  Blood       Date:  1984-09       Impact factor: 22.113

8.  Gastro-intestinal bleeding in acquired von Willebrand's disease: efficacy of high-dose immuno-globulin where substitution treatments failed.

Authors:  L A White; M Chisholm
Journal:  Br J Haematol       Date:  1993-06       Impact factor: 6.998

9.  Hypothyroidism as a cause of acquired von Willebrand's disease.

Authors:  R G Dalton; M S Dewar; G F Savidge; P B Kernoff; K B Matthews; M Greaves; F E Preston
Journal:  Lancet       Date:  1987-05-02       Impact factor: 79.321

10.  Acquired von Willebrand's syndrome associated with hydatid disease of the spleen--disappearance after splenectomy.

Authors:  C Richard; M C Sedano; M A Cuadrado; M Recio; V Hermosa; A Zubizarreta
Journal:  Thromb Haemost       Date:  1984-08-31       Impact factor: 5.249

View more
  1 in total

1.  Acquired von Willebrand's disease.

Authors:  B J Hennessy; B White; M Byrne; O P Smith
Journal:  Ir J Med Sci       Date:  1998 Apr-Jun       Impact factor: 1.568

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.